Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OLB vs ENSC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENSC Captures Overall Composite Edge (53.4 HOLD vs 48.6 HOLD), While OLB Leads 3–2 on Growth & Valuation Pillars

ENSC Overall Winner 6-Pillar Tally: OLB 3 – 2 ENSC (1 Tie) Matrix Metrics: OLB 3 – 6 ENSC

As of Nov 20, 2026, Ensysce Biosciences, Inc. (ENSC) captures the overall head-to-head institutional edge over The OLB Group, Inc. (OLB) on higher Unified Composite conviction (53.4/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 6–3 (led by Valuation Multiples, Growth & Scale), while OLB wins 3–2 across the 6-pillar growth and valuation breakdown. OLB trades at $0.12 (N/M Forward P/E, -73.3% operating margin) versus ENSC at $0.36 (0.8x Forward P/E, -281.3% operating margin).

  • Growth vs. Quality Trade-Off: ENSC earns the overall head-to-head edge with a stronger Unified Composite Score (53.4/100 HOLD vs. OLB 48.6/100 HOLD) and 0.98β · 79% Vol risk profile, whereas OLB leads top-line expansion (-43.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: OLB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.6); meanwhile ENSC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OLB vs ENSC
OLB NASDAQ
The OLB Group, Inc. Common Stock
Services-Business Services, Nec
$0.12
-4.33% 1D
Market Cap $3.8M
TTM Revenue $7.0M
Forward P/E N/M
Beta / 30D Vol 1.80β · 120% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 48.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.1%), weak momentum, RSI 30
RSI-14: 29.6 · SMA20: $0.19 · SMA50: $0.27
ENSC NASDAQ Head-to-Head Winner
Ensysce Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$0.36
-0.17% 1D
Market Cap $7.0M
TTM Revenue $4.5M
Forward P/E 0.8x
Beta / 30D Vol 0.98β · 79% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 50.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $0.39 · SMA50: $0.44

6-Pillar Scorecard Institutional Category Breakdown (OLB 3 – 2 ENSC)

Columns: Metric · OLB · ENSC
1. Valuation Multiples ENSC
Forward P/E N/M 0.8x
Trailing P/E N/M 0.8x
PEG Ratio N/M N/M
EV / Revenue 0.4x 1.4x
2. Growth & Scale ENSC
Revenue Growth (YoY) -43.6% -15.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $7.0M $4.5M
Market Cap $3.8M $7.0M
3. Profitability & Quality OLB
Gross Margin -30.9% N/A
Operating Margin -73.3% -281.3%
Net Profit Margin -68.2% -280.5%
Return on Equity (ROE) -70.8% -1295.1%
4. Balance Sheet & Cash Flow OLB
Cash Generation (TTM) -$2.6M -$9.7M
Cash Flow Margin -36.3% N/A
Net Cash / Leverage $1.1M Net Cash -$499,633 Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat OLB
OpEx & R&D Intensity 42.4% of Rev ($3.0M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Infrastructure Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OLB (3) vs ENSC (6)
Institutional Metric OLB ENSC Criterion Row Edge
Market Capitalization
Scale
$3.8M $7.0M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 0.8x Lower Multiple ENSC
Forward P/E Ratio
Valuation
N/M 0.8x Lower Multiple ENSC
Revenue Growth (YoY)
Growth
-43.6% -15.1% Higher Growth ENSC
Operating Margin (TTM)
Profitability
-73.3% -281.3% Higher Margin OLB
Net Profit Margin
Profitability
-68.2% -280.5% Higher Margin OLB
Return on Equity (ROE)
Capital Efficiency
-70.8% -1295.1% Higher ROE OLB
52-Week Range Position
Momentum
0% ($0–$2) 8% ($0–$2) Stronger Trend ENSC
Beta / 30D Volatility
Risk Regime
1.80β · 120% Vol 0.98β · 79% Vol Lower Realized Risk ENSC
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 53.4 / 100 (HOLD) Higher Composite ENSC
Trailing 12M Revenue (USD)
Operating Scale
$7.0M $4.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-30.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.4x EV/Rev N/M PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.6M ($1.1M Net Cash) -$9.7M (-$499,633 Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENSC +33.71 pp
OLB: -63.26% · ENSC: -29.55%
3M Horizon ENSC +61.06 pp
OLB: -61.34% · ENSC: -0.28%
6M Horizon ENSC +88.42 pp
OLB: -75.43% · ENSC: +12.99%
1Y Horizon ENSC +7.03 pp
OLB: -87.36% · ENSC: -80.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OLB Revenue ENSC Revenue OLB Op. Margin ENSC Op. Margin Margin Leader
FY2018 $10M N/A 5.9% N/A OLB
FY2019 $10M N/A -2.6% N/A OLB
FY2020 $10M $0M -7.5% -41.0% OLB
FY2021 $20M $0M -28.5% -562.7% OLB
FY2022 $30M $0M -26.9% -959.9% OLB
FY2023 $30M $0M -76.8% -480.5% OLB
FY2024 $10M $10M -90.9% -129.2% OLB
FY2025 $10M $10M -59.5% -202.1% OLB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OLB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OLB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENSC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OLB Moat Profile Cyclical / Execution-Driven Positioning
Software - Infrastructure Operator
Competes within the Software - Infrastructure value chain with $3.8M market capitalization and -73.3% operating margin.
OpEx & R&D Reinvestment 42.4% of Rev ($3.0M)
90D Engineering Disclosures 0 Published
ENSC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.0M market capitalization and -281.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OLB vs ENSC Key Questions & Quantitative Answers

As of Nov 20, 2026, Ensysce Biosciences, Inc. (ENSC) captures the overall head-to-head institutional edge over The OLB Group, Inc. (OLB) on higher Unified Composite conviction (53.4/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 6–3 (led by Valuation Multiples, Growth & Scale), while OLB wins 3–2 across the 6-pillar growth and valuation breakdown. OLB trades at $0.12 (N/M Forward P/E, -73.3% operating margin) versus ENSC at $0.36 (0.8x Forward P/E, -281.3% operating margin). Growth vs. Quality Trade-Off: ENSC earns the overall head-to-head edge with a stronger Unified Composite Score (53.4/100 HOLD vs. OLB 48.6/100 HOLD) and 0.98β · 79% Vol risk profile, whereas OLB leads top-line expansion (-43.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OLB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.6); meanwhile ENSC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ENSC leads the Growth & Scale pillar: OLB posts -43.6% YoY revenue growth and +0.0% YoY earnings growth on $7.0M TTM revenue (-30.9% gross margin, -73.3% operating margin), compared with ENSC at -15.1% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -281.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), OLB cumulative revenue shifted +0.0% while ENSC shifted +0.0%. In operating R&D and SG&A reinvestment, OLB deploys 42.4% of Rev ($3.0M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENSC.

ENSC screens cheaper on headline valuation multiples. OLB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (-36.3% FCF margin), whereas ENSC trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OLB (-70.8% ROE) versus ENSC (-1295.1% ROE) capital efficiency.

In options market volatility and institutional positioning, OLB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.80β · 120% Vol realized risk). By comparison, ENSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.